041960 — KOMIPHARM INTERNATIONAL Share Price
Last trade - 00:00- KR₩627bn
- KR₩643bn
- KR₩52bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.74 | ||
| Price to Tang. Book | 9.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.82 | ||
| EV to EBITDA | 210.68 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.52% | ||
| Return on Equity | -3.7% | ||
| Operating Margin | 0.82% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 35,847.4 | 39,800.52 | 42,647.03 | 58,778.55 | 52,465.29 | n/a | n/a | 7.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Company’s main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
Directors
- Yong Jin Yang CHM (61)
- Seong Cheol Moon CCE (55)
- Sang Hyeon Kim MDR (49)
- Yi Geun Park OTH (45)
- Su Jeong Kim DRC (40)
- Jeong Gi Yoo NID (66)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- September 21st, 1972
- Public Since
- October 30th, 2001
- No. of Shareholders
- 24,969
- No. of Employees
- 155
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 72,611,699
- Address
- 17, Gyeongje-ro, SIHEUNG, 15094
- Web
- https://www.komipharm.com/
- Phone
- +82 314986104
- Auditors
- KPMG Samjong Accounting Corp
Latest News for 041960
Upcoming Events for 041960
Q3 2026 Komipharm International Co Ltd Earnings Release
Q4 2026 Komipharm International Co Ltd Earnings Release
Komipharm International Co Ltd Annual Shareholders Meeting
Similar to 041960
AbClon
Korea Exchange - KOSDAQ
ADBiotech
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
AMINOLOGICS
Korea Exchange - KOSDAQ
FAQ
As of Today at 03:40 UTC, shares in KOMIPHARM INTERNATIONAL are trading at KR₩8,630. This share price information is delayed by 15 minutes.
Shares in KOMIPHARM INTERNATIONAL last closed at KR₩8,630 and the price had moved by +38.81% over the past 365 days. In terms of relative price strength the KOMIPHARM INTERNATIONAL share price has outperformed the FTSE Developed Asia Pacific Index by +3.08% over the past year.
There is no consensus recommendation for this security.
Find out moreKOMIPHARM INTERNATIONAL does not currently pay a dividend.
KOMIPHARM INTERNATIONAL does not currently pay a dividend.
KOMIPHARM INTERNATIONAL does not currently pay a dividend.
To buy shares in KOMIPHARM INTERNATIONAL you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩8,630, shares in KOMIPHARM INTERNATIONAL had a market capitalisation of KR₩627bn.
Here are the trading details for KOMIPHARM INTERNATIONAL:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 041960
Based on an overall assessment of its quality, value and momentum KOMIPHARM INTERNATIONAL is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like KOMIPHARM INTERNATIONAL. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -12.67%.
As of the last closing price of KR₩8,630, shares in KOMIPHARM INTERNATIONAL were trading +1.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The KOMIPHARM INTERNATIONAL PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩8,630.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
KOMIPHARM INTERNATIONAL's management team is headed by:
- Yong Jin Yang - CHM
- Seong Cheol Moon - CCE
- Sang Hyeon Kim - MDR
- Yi Geun Park - OTH
- Su Jeong Kim - DRC
- Jeong Gi Yoo - NID